New drug AZD5462 tested in kidney patients for safety
NCT ID NCT06661733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how the drug AZD5462 behaves in people with reduced kidney function compared to healthy volunteers. Sixteen participants received a single oral dose, and researchers measured drug levels in the blood and monitored for side effects. The goal was to understand if kidney impairment changes how the drug is processed, which helps guide future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5462
What this could lead to
If successful, this study could help determine the right dose of AZD5462 for people with kidney problems in future trials.
What could go wrong
This is a very early, small study (16 people) focused on drug levels and safety, not on treating any disease. Results may not apply to larger populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Sofia, 1612, Bulgaria